Thomas Ramdahl appointed Managing Director of Algeta ASA
GlobeNewswire - Fri Mar 14, 5:10AM CDT
Dr. Ramdahl succeeds Algeta's former CEO Andrew Kay.
Algeta ASA: Bayer's voluntary cash offer to acquire the entire issued share capital of Algeta is successful
GlobeNewswire - Wed Feb 26, 3:32AM CST
Algeta ASA ("Algeta"; OSE: ALGETA) today reported that Bayer has announced that 97.28% of all Algeta shares have been tendered to Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE under the voluntary cash offer (the "Offer") to acquire the entire issued share capital of Algeta for NOK 362 per share.
Algeta ASA : Algeta results for the fourth quarter and full year 2013
GlobeNewswire - Wed Feb 05, 12:20AM CST
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces its financial results for the fourth quarter and full year 2013.
Algeta ASA: Algeta announces change to Financial Calendar
GlobeNewswire - Mon Jan 20, 1:48AM CST
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces an update to its financial calendar.
Algeta ASA: Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta
GlobeNewswire - Mon Jan 20, 1:39AM CST
Algeta ASA ("Algeta"; OSE: ALGETA) today announced that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the voluntary cash offer (the "Offer") to acquire the entire issued share capital of Algeta for NOK 362 per share.
Algeta ASA: German competition authority clearance obtained for voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta
GlobeNewswire - Mon Jan 06, 12:02AM CST
Algeta ASA ("Algeta"; OSE: ALGETA) today announced that regulatory approval by German competition authorities, specifically the Federal Cartel Office (FCO), has been obtained. This was identified as a condition to the consummation of the voluntary cash offer (the "Offer") in the announcements dated 19 December 2013.
Bayer set to acquire cancer specialist Algeta
AP - Thu Dec 19, 4:14AM CST
BERLIN (AP) — Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion.
The Board of Directors of Algeta ASA unanimously recommends voluntary cash offer from Bayer to acquire the entire issued share capital of Algeta
GlobeNewswire - Thu Dec 19, 1:07AM CST
Intended for US media only
Germany's Bayer makes offer for Norway's Algeta
AP - Tue Nov 26, 5:02AM CST
BERLIN (AP) — Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion.
Algeta ASA: The Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG
GlobeNewswire - Tue Nov 26, 12:49AM CST
-- In response to recent media commentary, the Board of Directors of Algeta ASA confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG.
Algeta to host Capital Markets Days
Thomson Reuters ONE - Mon Nov 18, 12:01AM CST
Not intended for US media
Algeta ASA : Xofigo(R) (radium Ra 223 dichloride) injection granted Marketing Authorization in the European Union
GlobeNewswire - Fri Nov 15, 4:22AM CST
http://www.globenewswire.com/newsroom/ti?nf=M...UjMjc4NjE=
Algeta ASA: Xofigo® (radium Ra 223 dichloride) granted Marketing Authorization in the European Union
Thomson Reuters ONE - Fri Nov 15, 4:16AM CST
Not intended for US media